ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Search by Abstract Number Results

  • Abstract Number: L16 • ACR Convergence 2024

    Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial

    Megan Clowse1, David Isenberg2, Joan Merrill3, Thomas Dörner4, Michelle Petri5, Edward Vital6, Eric Morand7, Teri Jimenez8, Stephen Brookes9, Janine Gaiha-Rohrbach10, Christophe Martin11, Annette Nelde12 and Christian Stach13, 1Division of Rheumatology and Immunology, Duke University, Durham, NC, 2Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, 5Johns Hopkins University School of Medicine, Baltimore, MD, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 8UCB, Raleigh, NC, 9Biogen, Maidenhead, United Kingdom, 10Biogen, Cambridge, MA, 11UCB, Slough, United Kingdom, 12Biogen, Baar, Switzerland, 13UCB, Monheim am Rhein, Germany

    Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…
  • Abstract Number: L16 • ACR Convergence 2023

    Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease (WInS IgG4-RD): An Investigator-initiated, Multi-center, Open-label, Randomized Controlled Trial

    Linyi Peng1, Yuxue nie1, Jiaxin Zhou1, Lijun Wu2, Fang Wang3, Xiaomei Chen4, Jieqiong Li1, Yu Peng1, Hui Lu1, Lidan Zhao1, Mengtao Li1, Yan Zhao1, Xiaofeng Zeng5, Yunyun Fei1 and Wen Zhang1, 1Peking Union Medical College Hospital,Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China, 2Xinjiang Uygur Autonomous Region People's Hospital, XinJiang, China, 3Beijing Hospital, Beijing, China, 4Xinjiang Uygur Autonomous Region People's Hospital, Wulumuqi, China, 5Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China

    Background/Purpose: IgG4-related disease (IgG4-RD) is a fibroinflammatory disease. Remission induction treatment with glucocorticoid (GC) is usually effective, but its tendency of relapse makes the strategy…
  • Abstract Number: L16 • ACR Convergence 2022

    Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)

    Benjamin Terrier1, Laura Richert2, Grégory Pugnet3, Olivier Aumaitre4, Olivier Moranne5, Elisabeth Diot6, Alexandre Karras7, Fabrice Bonnet8, Claire De Moreuil9, Eric Hachulla10, Thomas Le Gallou11, Céline Lebas10, Francois Maurier12, Cédric Rafat7, Maxime Samson13, Jean-Francois Augusto14, Grégoire Couvrat-Devergne15, Cécile Janssen16, Thierry Martin17, Thomas Quemeneur18, Pierre-Louis Caron19, Cécile-Audrey Durel20, Khalil El Karoui7, Aurélie Grados21, Mathieu Puyade22, Virginie Rieu4, Yurdagul Uzunhan23, Jean-Francois Viallard8, Xavier Puéchal7, Loic Guillevin7, Noémie Huchet8, Hendy Abdoul7, Carine Bellera8, Frédéric Batteux7 and Odile Launay7, 1Cochin Hospital, Paris, France, 2EUCLID, Bordeaux, France, 3CHU, Toulouse, France, 4CHU, Clermont-Ferrand, France, 5CHU, Nimes, France, 6CHU, Tours, France, 7CHU, Paris, France, 8CHU, Bordeaux, France, 9CHU, Brest, France, 10CHU, Lille, France, 11CHU, Rennes, France, 12CH, Metz, France, 13CHU, Dijon, France, 14CHU, Angers, France, 15CH, La Roche sur Yon, France, 16CH, Annecy, France, 17CHU, Strasbourg, France, 18CH, Valenciennes, France, 19CHU, Grenoble, France, 20CHU, Lyon, France, 21CH, Niot, France, 22CHU, Poitiers, France, 23CHU, Bobigny, France

    Background/Purpose: Patients receiving glucocorticoids plus rituximab (RTX) show an increased risk of infection, especially invasive pneumococcal infections. Vaccine responses to influenza, Streptococcus pneumoniae and SARS-CoV-2…
  • Abstract Number: L16 • ACR Convergence 2021

    Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository

    Jasvinder Singh1, Namrata Singh2, Alfred Anzalone3, Amy Olex4, Jing Sun5, Vithal Madhira6 and Rena Patel7, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Washington, Bellevue, WA, 3University of Nebraska, Omaha, NE, 4Virginia Commonwealth University, Richmond, VA, 5Johns Hopkins University, Baltimore, MD, 6Palila Software, Reno, NV, 7Unviersity of Washington, Seattle, WA

    Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
  • Abstract Number: L16 • 2019 ACR/ARP Annual Meeting

    GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study

    Samuel Deshayes1, Venceslas Bourdin 2, Christian Creveuil 3, Jonathan Boutemy 1, Eric Liozon 4, Xavier Kyndt 5, Laurent Sailler 6, Grégory Pugnet 6, Hubert de Boysson 1, Eric Hachulla 7, Marc André 8, Julie Magnant 9, Jacques Boddaert 10, Olivier Fain 11, Arsène Mékinian 11, Mohamed Hamidou 12, Loïc Guillevin 13, Cédric Landron 14, Isabelle Marie 15, Yannick Chène 3, Laurent Becquemont 16, Céline Verstuyft 2 and Boris Bienvenu 17, 1Department of Internal Medicine, Caen University Hospital, Caen, France, 2INSERM UMR_S1178, Medicine Faculty, CESP, Paris-Sud University, Le Kremlin Bicêtre, Paris, France, 3Biomedical Reserch Unit, Caen University Hospital, Caen, France, 4Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France, 5Department of Internal Medicine and Nephrology, Valenciennes Hospital, Valenciennes, France, 6Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, 7Department of Internal Medicine and Clinical Immunology, Lille University Hospital, Lille, France, 8Department of Internal Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, 9Department of Internal Medicine, Tours University Hospital, Tours, France, 10Department of Geriatrics, Pitié-Salpêtrière-Charles Foix University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, 11Department of Internal Medicine, Saint Antoine University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, 12Department of Internal Medicine, Nantes University Hospital, Nantes, France, 13Department of Internal Medicine, Cochin University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, 14Department of Internal Medicine, Poitiers University Hospital, Poitiers, France, 15Department of Internal Medicine, Rouen University Hospital, Rouen, France, 16INSERM UMR_S1178, Medicine Faculty, CESP, Paris-Sud University, Le Kremlin Bicêtre, Le Kremblin Bicêtre, France, 17Department of Internal Medicine, Saint Joseph Hospital, Marseille, France

    Background/Purpose: Giant cell arteritis (GCA) is the most common cause of primary vasculitis in adults. Corticosteroids are the cornerstone of the treatment. However, approximately 50%…
  • Abstract Number: L16 • 2018 ACR/ARHP Annual Meeting

    Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness

    Dawn McGuire1, Neil Segal2, Samy Metyas3, Hans Richard Barthel4, Meghan Miller5, David Rosen5 and Yoshi Kumagai5, 1Orthotrophix, Incorporated, Oakland, CA, 2Physical Medicine and Rehabilitation, University of Kansas Medical Center, Kansas City, KS, 3Medvin Clinical Research, Covina, CA, 4Barthel Clinic, Santa Barbara, CA, 5OrthoTrophix, Incorporated, Oakland, CA

    Background/Purpose: TPX-100, a peptide derived from Matrix Extracellular Phosphoglycoprotein (MEPE), has been shown to induce articular cartilage regeneration after cartilage injury in animal models. A…
  • Abstract Number: L16 • 2013 ACR/ARHP Annual Meeting

    Kidney Resident B Cells and Plasmacytoid Dendritic Cells  in Urine of Systemic Lupus Erythematosus  patients

    Eric Scott1, Mary Anne Dooley2 and Steve Clarke1, 1Microbiology/Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Chapel Hill, NC

    Title: Kidney resident B Cells and plasmacytoid dendritic cells (pDCs) in the urine of systemic lupus erythematosus (SLE) patients. Background/Purpose: Renal involvement remains the principal…
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology